Keywords: Bristol-Myers Squibb, Orencia, European approval, polyarticular juvenile idiopathic arthritis
European Commission approves Bristol-Myers Squibb’s Orencia for combination use in pJIA
Article | 26 January 2010
US drug major Bristol-Myers Squibb says that the European Commission has approved Orencia (abatacept) in combination with methotrexate for the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
